No Data
TYK Medicines Secures Hong Kong Exchange Listing Approval for Over 173.6 Million H Shares
TYK MEDICINES-B (02410.HK): The Stock Exchange has granted listing approval for the implementation of full circulation of H shares.
Gelonghui, February 10 - TYK MEDICINES-B (02410.HK) announced that the company has applied to the Listing Committee of the Stock Exchange for approval to list and trade 173,641,645 H shares ("Converted H Shares") resulting from the conversion of 173,641,645 unlisted shares held by 25 Shareholders. The Stock Exchange granted the listing approval on February 10, 2025.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Tongyuan Kang Medical was invited to attend the 43rd JPMorgan Medical Health Conference (JPM Conference).
Shanghai and San Francisco, January 24, 2025 /PR Newswire/ -- Zhejiang Tongyuan Kang Medical Technology Co., Ltd. (hereinafter referred to as "Tongyuan Kang Medical", stock code: 2410.HK) is honored to be invited to participate in the 43rd JPMorgan Healthcare Conference held in San Francisco, USA. Dr. Wu Yusheng, the founder and Chairman of Tongyuan Kang Medical, participated in a roundtable discussion and gave a speech at the conference, discussing the latest developments in the biopharmaceutical field with experts in the industry.
Most pharmaceutical stocks rose, with Tongyuan Kangyi Medicine (02410) up 18.46%. Institutions pointed out that the policy trend of medical insurance funds supporting innovative drugs will not change.
Jingwu Cai Xun | Most pharmaceutical stocks rose, with Tongyuan Kang Medicine (02410) up 18.46%, Keji Pharmaceutical (02171) up 13.86%, Heyu (02256) up 11.79%, Cloud Peak Xin Yao (01952) up 10.31%, cansinobio (06185) up 7.48%. Zhong Yin International stated that benefiting from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity industry, is expected to outperform the market. The bank believes that the performance of the macroeconomy is closely related to the revenue and expenditure of medical insurance funds and medical health consumer spending. As policy focus shifts to stimulating the economy, the bank believes that medical industry
TYK MEDICINES-B: Interim Report 2024
